Form 4: Supernus Officer Frank Mottola Reports RSU Vesting, Tax Sales

Supernus Pharmaceuticals SVP Frank Mottola reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Frank Mottola, SVP, Chief Tech. Ops. Officer of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions related to the vesting of Restricted Stock Units (RSUs).
• On February 24, 2026, a total of 3,125 RSUs vested, converting into 3,125 shares of Supernus common stock.
• Concurrently, 1,641 shares of common stock were disposed of at prices of $51.35 and $50.86 to satisfy tax withholding requirements associated with the RSU vesting.
• Following these transactions, Mr. Mottola directly beneficially owns 17,208 shares of Supernus common stock.
• Remaining derivative holdings include 3,375 Restricted Stock Units from a grant that began vesting on February 19, 2026, and 2,500 Restricted Stock Units from a grant that began vesting on February 22, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine and expected insider transaction related to executive compensation and tax obligations, with no direct positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of 3,125 Restricted Stock Units represents a realization of equity compensation for the SVP, Frank Mottola.
• The acquisition of common stock at a $0 price indicates the conversion of previously granted equity awards into direct ownership.

Negatives

• A portion of the vested shares (1,641 shares) was sold to cover tax withholding obligations, which is a standard practice but reduces the net shares retained by the officer.

Future Outlook

The filing indicates future vesting events for remaining Restricted Stock Units, with installments continuing from grants that began vesting on February 19, 2026, and February 22, 2025.

Industry Context

StockSavvy.ai notes that insider transaction reports like Form 4 are routine disclosures for publicly traded companies, reflecting executive compensation and ownership changes. These transactions are common across the pharmaceutical industry as part of executive incentive programs.

Stakeholder Impact

• Shareholders: This filing provides transparency into executive compensation and ownership, which is generally positive for corporate governance. The transactions themselves are routine and unlikely to have a significant direct impact on the company's stock price or operations.

Next Steps

• Future installments of Restricted Stock Units will continue to vest according to their respective schedules, specifically for grants that began vesting on February 19, 2026, and February 22, 2025.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Frank Mottola, Restricted Stock Units, RSU vesting, Insider transaction, Form 4, Equity compensation, Tax withholding